Aslan Fred sold $469K of ARTV

Aslan Fred (Chief Executive Officer) sold 119,771 shares of Artiva Biotherapeutics, Inc. (ARTV) at $3.91 ($0.47M total) on 2026-11-17.

Original reporting
SEC EDGAR · Aslan Fred
Published Nov 18, 2026, 9:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
medium confidence
Mentioned
$ARTV
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The disclosure updates the record of insider selling activity by the CEO, which can influence short-term sentiment but does not change fundamentals based on the provided text.

02

Market read

Traders may monitor for follow-on insider activity or concurrent company catalysts, but this filing alone is unlikely to drive a sustained repricing.

03

What to watch

Absence of a stated 10b5-1 plan could increase speculation, but without follow-on filings or company news, traders may overinterpret the signal.

Relevance 4/10Novelty 5/10Timing: filed after-hours on 2026-11-18, reflecting trades dated 2026-11-17

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Artiva Biotherapeutics, Inc.

Company-level read

Ticker impact

$ARTVNeutralMedium confidence
Context

Artiva Biotherapeutics CEO Aslan Fred filed a Form 4 selling 119,771 shares for about $468.5K at $3.9119 per share.

Expected impact

Likely limited near-term impact, with any move driven more by broader market/biotech sentiment than the sale size.

Evidence & confidence

The filing discloses an executive sale amount and price, but provides no new operational, regulatory, or financial guidance; it is not described as part of a 10b5-1 plan.

Market effects

Minimal spillover to biotech peers; insider-sale Form 4s are common and usually not sector-moving without additional company-specific catalysts.

No clear regional market linkage beyond typical US small/mid-cap biotech sentiment.

Low, as the disclosure is company-specific and US SEC filing based.

Counterpoint

The sale may be routine liquidity management and not a bearish signal, especially since the article provides no context on motivations or future trading plans.

Key entities

  • Artiva Biotherapeutics, Inc.

    US-listed biotech company whose CEO insider sale is disclosed on Form 4.

  • Aslan Fred

    CEO and officer/director who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.